Home›Stock Screener›Bal Pharma

Bal Pharma Share Price Today | Stock Price & Bal Pharma Share Screener

BALPHARMA Pharmaceuticals
Live Share Price NSE
₹105.74
▼ -3.79 (-3.46%)
2026-10-01 00:00:00
Live Share Price BSE
₹107.60
▲ 2.00 (1.89%)
2026-10-05 00:00:00

As of October 1, 2026, the live Bal Pharma share price (NSE: BALPHARMA) is ₹105.74 on NSE and ₹107.60 on BSE, down 3.46% from the previous close, with shares trading between ₹104.51 and ₹110.00 in today's trading session, and a 52-week range of ₹60.42–₹114.45. Check BALPHARMA 52-week high low for the annual price range and momentum. Use the Bal Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Bal Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹84 and net income of ₹4, with EBITDA of ₹10, an operating margin of 13.0% and a profit margin of 4.8%.

Bal Pharma Market Cap ₹168.30 Cr.
BALPHARMA P/E Ratio (TTM) 23.21
Bal Pharma P/B Ratio 2.04
EPS (TTM) ₹3.95
Dividend Yield 1.14%
Debt to Equity 1.94
BALPHARMA 52 Week High ₹114.45
Bal Pharma 52 Week Low ₹60.42
Operating Margin 13.00%
Profit Margin 4.76%
BALPHARMA Revenue (TTM) ₹84.00
EBITDA ₹10.00
Net Income ₹4.00
Total Assets ₹376.00
Total Equity ₹82.00

Bal Pharma Share Price Chart

Track the current stock price of Bal Pharma with an interactive chart. Analyse BALPHARMA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Bal Pharma stock quote in one place.

The quote of ₹105.74 sits between the 52-week low of ₹60.42 and the 52-week high of ₹114.45, and the latest session moved -3.46% from the previous close.

Bal Pharma Company Profile - Fundamental Screener

Screen Bal Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BALPHARMA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE083D01012.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE083D01012

Bal Pharma Balance Sheet Screener

Screen BALPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹376, up from ₹336 in 2025.

Latest statistics put total assets at ₹376 and shareholder funds at ₹82, with a leverage ratio of 1.94.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 376 336 320 313 261 240 238 261 260 233
Current Assets 262 235 234 228 185 164 157 183 185 165
Fixed Assets 98 87 80 77 67 69 71 70 72 60

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 44 39 45 40 36 34 34 38 46 30
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 82 77 72 64 59 53 45 60 60 60
Share Capital 16 16 16 16 15 15 14 14 14 14
Reserves & Surplus 66 62 56 48 43 38 38 53 51 48

Bal Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Bal Pharma income statement and profit fundamentals. Analyze BALPHARMA quarterly results. Bal Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹84 and net profit was ₹4, equal to earnings per unit of ₹2.26, at an operating margin of 13%.

In that period expenses were ₹74, interest cost ₹4 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹89 and net profit of ₹1.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar

Revenue and Expenses

Revenue 84 89 83 67 75 88 97 75 74 74 83 71 93 82 78
Expenses 74 81 74 60 68 78 85 68 66 65 74 64 85 74 71

Operating Costs and Margins

EBITDA 10 8 9 7 7 10 12 7 8 8 8 7 8 8 7
Operating Profit % 13.00% 9.00% 9.00% 9.00% 8.00% 11.00% 10.00% 9.00% 10.00% 11.00% 10.00% 9.00% 8.00% 10.00% 5.00%
Depreciation 3 3 2 3 2 3 2 2 3 3 2 3 2 3 2
Interest 4 5 4 4 4 5 4 4 4 5 4 4 4 4 3

Profit and Earnings

Profit Before Tax 3 1 3 0 1 2 6 1 1 1 2 0 2 1 2
Tax 0 0 -3 0 0 0 0 0 0 0 1 0 1 0 0
Net Profit 4 1 5 0 1 2 6 0 1 1 2 0 1 1 2
EPS 2.26 0.71 3.40 0.13 0.45 1.12 3.73 0.16 0.65 0.33 1.03 0.06 0.62 0.54 1.33

Bal Pharma Cash Flow Screener - Liquidity Fundamentals

Screen BALPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities generated ₹20, and net cash flow was an outflow of ₹2.

Over the same period, investing activities used ₹15 and financing activities used ₹8.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March

Cash from Operations and Investing

Operating Activities 20 23 -2 27 22 23 8 1 6 -19
Investing Activities -15 -19 -22 -10 -6 -5 -8 -4 -8 -14

Financing and Net Cash

Financing Activities -8 -1 24 -17 -17 -20 0 4 -6 32
Net Cash Flow -2 3 0 0 0 -2 0 1 -8 -1

Bal Pharma Shareholding Pattern Screener

See Bal Pharma shareholding pattern with promoter, FII, and DII holdings. Check Bal Pharma promoter holding and ownership changes for BALPHARMA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 50.86%, foreign institutions 0.14%, domestic institutions 0.00% and the public 32.84%, spread across 15,214 shareholders.

The shareholder count was 15,214 in 2026-Mar, compared with 14,974 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 50.86% 50.86% 50.86% 50.86% 50.86% 50.86% 51.23% 51.23%

Institutional Investors

FII Holding 0.14% 0.15% 0.14% 0.15% 0.22% 0.14% 0.13% 0.13%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 32.84% 32.86% 32.49% 32.41% 32.97% 33.02% 32.15% 32.36%
Other Holding 16.16% 16.13% 16.51% 16.58% 15.94% 15.99% 16.49% 16.28%
Shareholder Count 15,214 14,974 15,723 15,826 15,774 15,520 14,772 15,014

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Bal Pharma. Bal Pharma dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹1.20 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹1.20 and ₹1.20 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹1.20 1.99%
2024-March ₹1.20 1.43%
2023-March ₹1.00 1.10%
2022-March ₹1.00 1.55%
2021-March ₹1.00 0.93%
2020-March ₹0.00 0.00%
2019-March ₹1.00 3.13%
2018-March ₹1.00 1.43%
2017-March ₹1.00 1.30%

Bal Pharma Stock Index Membership - Nifty & Sensex

See which indices include Bal Pharma stock. Check BALPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Bal Pharma is not part of any tracked indices.
Only major market indices are tracked in our system.

Bal Pharma Market Events Screener - Corporate Actions

Get Bal Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Bal Pharma stock events that may affect BALPHARMA share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 24, 2026, with a record date of September 24, 2026.

It is followed by Dividend dated September 17, 2026 and Quarterly Result Announcement dated August 12, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-24 2026-09-24 Annual General Meeting NA 24.87%
2026-09-17 2026-09-17 Dividend ₹ 1.20 /share 10.22%
2026-08-12 2026-08-12 Quarterly Result Announcement NA -1.12%
2026-05-27 2026-05-27 Quarterly Result Announcement NA 17.37%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 7.85%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -1.70%
2025-09-25 2025-09-25 Annual General Meeting NA -9.36%
2025-09-18 2025-09-18 Dividend ₹ 1.20 /share -6.50%
2025-08-11 2025-08-11 Quarterly Result Announcement NA -3.59%
2025-05-29 2025-05-29 Quarterly Result Announcement NA -6.14%
2025-02-13 2025-02-13 Quarterly Result Announcement NA -12.62%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -7.93%
2024-09-25 2024-09-25 Annual General Meeting NA 14.26%
2024-09-17 2024-09-19 Dividend ₹ 1.20 /share 31.47%
2023-12-21 2023-12-21 Extraordinary General Meeting NA -10.17%

Bal Pharma Competitors Screener - Peer Stocks Comparison

Screen BALPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 432,120 35.84 61,674 12.69% 11,565 36.68
Divis Laboratories 245,532 84.36 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 181,333 84.01 13,886 20.34% 2,138 41.12
Zydus Life Science 114,284 24.88 27,658 17.64% 5,026 47.64
Cipla 108,576 32.42 29,045 2.24% 3,870 34.78
Laurus Labs 107,198 98.56 6,868 22.01% 890 58.70
Mankind Pharma 104,707 50.48 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,679 31.47 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,479 25.97 34,145 5.56% 3,503 50.30
Lupin 92,885 16.71 29,039 26.75% 5,356 31.59

Bal Pharma Company Announcements - News & Reports Screener

Screen BALPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated September 27, 2026.

The next most recent announcements are dated September 27, 2026 and September 27, 2026.

Date Update Actions
2026-09-27 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-09-27 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-27 Closure of Trading Window -
2026-09-26 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-10 Clarification Regarding Movement In Price -
2026-09-10 Clarification sought from Bal Pharma Ltd -
2026-09-07 Announcement under Regulation 30 (LODR)-Allotment -
2026-08-27 Intimation Of Record Date For Final Dividend -
2026-08-26 Reg. 34 (1) Annual Report. -
2026-08-26 Bal Pharma Limited - Notice Of AGM -
2026-08-26 Intimation - 39Th AGM Scheduled On 24Th September 2026 -
2026-08-25 Clarification With Respect To Tentative Timeline For Utilization Of Net Proceeds Of Preferential Issue -
2026-08-13 Newspaper Publications - Unaudited Financial Results 30Th June 2026 And IEPF Notice -
2026-08-12 Financial Result For The Quarter End 30Th June 2026 -
2026-08-12 Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday August 12 2026 -
2026-08-10 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-08-10 Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot -
2026-08-05 Board Meeting Intimation for Considering Inter-Alia The Unaudited (Standalone And Consolidated) Financial Statements Of The Company For The First Quarter Ended 30Th June 2026 And Other General Business Matters -
2026-07-30 Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 : Intimation Regarding Notice Of Postal Ballot -
2026-07-23 Intimation Regarding Corrigendum To The Postal Ballot Notice -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹105.74, within a 52-week range of ₹60.42 to ₹114.45. The P/E ratio is 23.21 and the P/B ratio is 2.04, with earnings per unit of ₹3.95. Market capitalisation stands at ₹168.30 Cr and the dividend yield is 1.14%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.